September 2020 Awareness Night HIFU-The Prostate Cancer Lumpectomy! Focused treatment to kill the cancer – NOT-your Quality of Life Dr. Jack Barkin, MD, FICS, FACS, DABU, MHM, CCPE, FRCS Clinical Professor, Department of Surgery, University of Toronto Urologic/ Robotic Surgeon, Humber River Hospital Executive Editor-in-Chief, Canadian Journal of Urology Medical Director, Can-Am HIFU, HIFU Proctor This Awareness Night was held on the Zoom platform. The session will include a Q and A component. CLICK ON THE ARROW TO START THE VIDEO The Complete Presentation time is 2:12:09 <
July 2020 Awareness Night Brachytherapy: The evolving roles of Brachytherapy for prostate cancer: teaching an old dog even newer tricks! Dr. Alejandro Berlin, MD, MScClinician-Scientist Radiation Medicine Program, Princess Margaret Cancer Centre Asst. Professor, Dept. of Radiation, U. of Toronto This Awareness Night was held on the Zoom platform. The session will include a Q and A component. CLICK ON THE ARROW TO START THE VIDEOThe Complete Presentation time is 1:22:23 <
A new study of this pioneering new approach uses sound waves to heat and destroy tumors and leaves the healthy surrounding tissue untouched according to Science Daily. This minimally invasive method that is called MRI-guided transurethral ultrasound ablation (TULSA) relies on a rod-shaped device that is inserted directly into the urethra and are controlled by a software algorithm. What’s even more remarkable is that the entire procedure — called Tulsa-pro – is done in an MRI scanner and not in an operating room. This treatment is not available in North America at present. Read the article.
July 2017 Awareness Night Partial gland ablation for localized prostate cancer: Who is eligible and what are the risks? Dr. Nathan Perlis, MD, MSc, FRCSC Clinical assistant, Division of Urology, University Health Network Clinical fellow, Society of Urological Oncology, University of Toronto CLICK ON THE ARROW TO START THE VIDEO The Complete Presentation 40:48 minutes
The challenge in prostate cancer (PCa) is to match the aggressiveness of the treatment to that of the cancer. Until recently, all screen-diagnosed localized cancers were considered at least potentially aggressive and in most cases were treated radically. Active surveillance represented a major step forward in acknowledging that some cancers were clinically insignificant and did not pose a threat to the patient’s life. Recently, a third option—focal therapy—has emerged as a potential middle ground between radical treatment and active surveillance. Read the article.